Allergen-specific Immunoglobulin E recognizing Der f 1 and Der f 2 epitopes (Der f 1/2-specific IgE)

Allergen-specific Immunoglobulin E (IgE) recognizing Der f 1 and Der f 2 epitopes is a specialized class of antibodies central to the allergic response against the house dust mite Dermatophagoides farinae (Thomas et al., 2002). Der f 1, a cysteine protease, and Der f 2, a member of the NPC2 family, are the primary allergens responsible for sensitization in the majority of mite-allergic patients (Jeong et al., 2012). These IgE antibodies bind to high-affinity FcεRI receptors on mast cells and basophils; when cross-linked by the allergens, they trigger the release of inflammatory mediators such as histamine, leading to symptoms of asthma and rhinitis (Gould & Sutton, 2008). Therapeutic intervention often involves monoclonal antibodies like omalizumab, which bind the Fc region of IgE to prevent receptor attachment, or allergen-specific immunotherapy (AIT) using standardized extracts like Odactra to induce immune tolerance (Durham & Shamji, 2023). This process shifts the immune response from a Th2-driven IgE production toward a Th1/Treg-driven production of protective IgG4 antibodies. Monitoring these specific IgE levels is crucial for diagnosing mite allergy and assessing the efficacy of desensitization treatments.

Other names

Anti-Der f 1 IgEAnti-Der f 2 IgEHouse dust mite-specific IgEDermatophagoides farinae-specific IgEDer f 1/2-specific IgE

Therapeutic agents target this molecule by either non-specifically sequestering circulating IgE to prevent its binding to high-affinity FcεRI receptors on mast cells and basophils, or by using allergen-specific immunotherapy to induce immune tolerance, which reduces the production of allergen-specific IgE and increases the levels of protective, competing IgG4 antibodies (Gould & Sutton, 2008; Durham & Shamji, 2023).